---
figid: PMC6007953__oncotarget-09-27319-g001
figtitle: XIAP regulates apoptotic and inflammatory signaling pathways
organisms:
- NA
pmcid: PMC6007953
filename: oncotarget-09-27319-g001.jpg
figlink: /pmc/articles/PMC6007953/figure/F1/
number: F1
caption: XIAP is an inhibitor of caspases 3, 7, and 9, which allows it to block both
  mitochondrial and death receptor mediated cell killing. By serving as an E3 ligase
  for RIP2, XIAP is a critical mediator of NOD2/RIP2 inflammatory signaling. Consequently,
  XIAP selective antagonists can efficiently inhibit NOD2 pathway.
papertitle: XIAP at the crossroads of cell death and inflammation.
reftext: Domagoj Vucic. Oncotarget. 2018 Jun 8;9(44):27319-27320.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.973901
figid_alias: PMC6007953__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6007953__F1
ndex: 6d2dbddb-dec1-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6007953__oncotarget-09-27319-g001.html
  '@type': Dataset
  description: XIAP is an inhibitor of caspases 3, 7, and 9, which allows it to block
    both mitochondrial and death receptor mediated cell killing. By serving as an
    E3 ligase for RIP2, XIAP is a critical mediator of NOD2/RIP2 inflammatory signaling.
    Consequently, XIAP selective antagonists can efficiently inhibit NOD2 pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TNF
  - TNFRSF1A
  - TRADD
  - TRAF2
  - TANK
  - DPEP1
  - ADA2
  - BIRC2
  - BIRC3
  - NOD2
  - ALPI
  - ALPP
  - CD47
  - IAPP
  - MAGT1
  - UQCRFS1
  - RIPK1
  - RALBP1
  - KRR1
  - FADD
  - XIAP
  - RIPK2
  - ARHGEF28
  - BCL2
  - BCL2L1
  - DIABLO
  - NFKB1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CASP3
  - CASP7
  - XIAP
---
